drugset / Trial / NCT00263783
Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine the safety profile of single and multiple doses of MEDI522 in patients with refractory solid tumors.
Timeline
- Start
- 2001-03
- Primary completion
- 2002-04
- Completion
- 2002-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | etaracizumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | etaracizumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | etaracizumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | etaracizumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | etaracizumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | etaracizumab | Monoclonal antibody | 10 mg/kg | Intravenous |